Search research articles
Contact Us
Filters
Showing results (61-70 of 98) with videos related to
Page
of 10
Sort By:
Joint Bone Spine
|
March 21, 2026
Serum biomarkers fail to predict response to adalimumab in axial spondyloarthritis: results from discovery and validation cohorts
Athan Baillet, Minh Vu Chuong Nguyen, Anaïs Courtier, et al.
Pharmaceutics
|
November 27, 2021
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
David Ternant, Olivier Le Tilly, Laurence Picon, et al.
Joint Bone Spine
|
September 22, 2014
Management of osteoporosis in women after forearm fracture: data from a French health insurance database
Florence Erny, Aurélie Auvinet, Delphine Chu Miow Lin, et al.
Clinical and Translational Science
|
February 27, 2020
Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
Stéphane Paul, Hubert Marotte, Arthur Kavanaugh, et al.
Therapeutic Drug Monitoring
|
March 11, 2010
Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis
Denis Mulleman, Delphine Chu Miow Lin, Emilie Ducourau, et al.
International Journal of Rheumatology
|
November 12, 2016
Impact of Anti-Inflammatory Drugs on Pyogenic Vertebral Osteomyelitis: A Prospective Cohort Study
Aurélien Dinh, Maxime Jean, Frédérique Bouchand, et al.
British Journal of Clinical Pharmacology
|
August 27, 2025
Therapeutic drug monitoring education: The current state
Guenka Petrova, Stiliyana Blagova, Konstantin Tachkov, et al.
British Journal of Clinical Pharmacology
|
September 17, 2014
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis
David Ternant, Emilie Ducourau, Piéra Fuzibet, et al.
Clinical Pharmacokinetics
|
November 13, 2021
The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition
Amina Bensalem, Guillaume Cartron, Ulrich Specks, et al.
Clinical Pharmacokinetics
|
August 5, 2021
Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model
David Ternant, Marc Pfister, Olivier Le Tilly, et al.
Page
of 10
Search research articles
Search
Showing results (61-70 of 98) with videos related to
Sort By:
Page
of 10
Joint Bone Spine
|
March 21, 2026
Serum biomarkers fail to predict response to adalimumab in axial spondyloarthritis: results from discovery and validation cohorts
Athan Baillet, Minh Vu Chuong Nguyen, Anaïs Courtier, et al.
Pharmaceutics
|
November 27, 2021
Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model
David Ternant, Olivier Le Tilly, Laurence Picon, et al.
Joint Bone Spine
|
September 22, 2014
Management of osteoporosis in women after forearm fracture: data from a French health insurance database
Florence Erny, Aurélie Auvinet, Delphine Chu Miow Lin, et al.
Clinical and Translational Science
|
February 27, 2020
Exposure-Response Relationship of Certolizumab Pegol and Achievement of Low Disease Activity and Remission in Patients With Rheumatoid Arthritis
Stéphane Paul, Hubert Marotte, Arthur Kavanaugh, et al.
Therapeutic Drug Monitoring
|
March 11, 2010
Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis
Denis Mulleman, Delphine Chu Miow Lin, Emilie Ducourau, et al.
International Journal of Rheumatology
|
November 12, 2016
Impact of Anti-Inflammatory Drugs on Pyogenic Vertebral Osteomyelitis: A Prospective Cohort Study
Aurélien Dinh, Maxime Jean, Frédérique Bouchand, et al.
British Journal of Clinical Pharmacology
|
August 27, 2025
Therapeutic drug monitoring education: The current state
Guenka Petrova, Stiliyana Blagova, Konstantin Tachkov, et al.
British Journal of Clinical Pharmacology
|
September 17, 2014
Pharmacokinetics and concentration-effect relationship of adalimumab in rheumatoid arthritis
David Ternant, Emilie Ducourau, Piéra Fuzibet, et al.
Clinical Pharmacokinetics
|
November 13, 2021
The Influence of Underlying Disease on Rituximab Pharmacokinetics May be Explained by Target-Mediated Drug Disposition
Amina Bensalem, Guillaume Cartron, Ulrich Specks, et al.
Clinical Pharmacokinetics
|
August 5, 2021
Infliximab Treatment Does Not Lead to Full TNF-α Inhibition: A Target-Mediated Drug Disposition Model
David Ternant, Marc Pfister, Olivier Le Tilly, et al.
Page
of 10